1. Scrip
  2. >>Business

Moderna Looks To mRNA To Crack Challenge Of HIV Vaccine

mRNA Will Speed Development Time

 
• By Andrew McConaghie

The Bill Gates Foundation-backed partnership with IAVI could bring a HIV vaccine a step closer, but generating the right antibody response has defeated many previous attempts.

Moderna believes its mRNA know-how, which has proven so successful against COVID-19, could also help finally crack the challenge of developing a HIV vaccine, and has just launched a Phase I study with academic partners.

While antiretroviral therapies are able to suppress HIV for a lifetime once individuals are infected, there remains a need for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.